Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1542/pir.26-9-341 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer. HER2-targeted therapies have shown clinical activity against these tumor types, resulting in regulatory approvals. However, the efficacy of HER2 therapies in tumors with HER2 mutations has not been widely investigated.
View Article and Find Full Text PDFSwitching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations.
BMJ Open Ophthalmol
January 2025
Ophthalmology & Vision Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Dual inhibition of the angiopoietin (Ang)/Tie and vascular endothelial growth factor (VEGF) signalling pathways in patients with retinal diseases, such as neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME), may induce greater vascular stability and contribute to increased treatment efficacy and durability compared with treatments that only target the VEGF pathway. Faricimab, a bispecific intravitreal agent that inhibits both VEGF and Ang-2, is the first injectable ophthalmic drug to achieve treatment intervals of up to 16 weeks in Phase 3 studies for nAMD and DME while exhibiting improvements in visual acuity and retinal thickness. Data from real-world studies have supported the safety, visual and anatomic benefits and durability of faricimab, even in patients who were previously treated with other intravitreal agents.
View Article and Find Full Text PDFBalancing anticancer therapy efficacy and safety in advanced hepatocellular carcinoma: a case report.
J Gastrointest Oncol
December 2024
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background: Hepatocellular carcinoma (HCC) is a significant health problem associated with several risk factors, increasingly driven by non-alcoholic steatohepatitis and metabolic syndrome. This association poses a challenge for the primary treatments of HCC, which may include immune checkpoint inhibitors and vascular endothelial growth factor inhibitors, due to their potential cardiotoxic effect. Therefore, it is imperative to balance the therapeutic effects of these agents with their potential cardiovascular adverse events.
View Article and Find Full Text PDFExploring how structural forms of power shape the training of intraprofessional collaboration between family physicians and specialty physicians in outpatient workplace settings.
Med Educ
January 2025
The Institute for Education Research, University Health Network, Toronto, Canada.
Introduction: Intraprofessional collaboration between family physicians (FPs) and specialist physicians (SPs) is posited to improve patient outcomes but is hindered by power dynamics. Research informing intraprofessional training on hospital wards often conceptualizes power at an interactional level. However, less is known about how social structures make these power dynamics possible.
View Article and Find Full Text PDFPardon my trench: reflections on the uptake of trenchless technologies in the Norwegian water sector.
Water Sci Technol
January 2025
Department of Civil and Environmental Engineering, Norwegian University of Science and Technology, S.P. Andersens veg 5, 7031 Trondheim, Norway.
Trenchless pipe renewal can be a more cost-, time- and environmentally effective alternative to traditional open-cut replacement. It reduces service disruptions for surrounding infrastructures and is often cheaper, especially when extensive excavation works are necessary, particularly in cold climates, like Norway, where trenches are traditionally deep due to frost security requirements. Still, the uptake of trenchless technologies is still limited in the Norwegian market.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!